A NEW IDEA ON BIOTECH CYTK — GOOD TRIAL DATA — BUYOUT TARGET
By Nigam Arora CYTK is demonstrating good trial data in patients with obstructive hypertrophic cardiomyopathy. The data shows aficamten is superior to the current standard of care beta blockers. CYTK is a buyout target. To date, 205 Arora portfolio companies have been bought out. Producing a fortune for members who routinely
May 13, 2025